Frédérique Berger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Frédérique Berger has a total of 416 co-authors. Here are the top co-authors by number of shared publications:
- François-Clément Bidard
Translational Research Department, Laboratory of Circulating Tumor Biomarkers, Inserm CIC 1428, Institut Curie, Paris, France
17 shared publications Jean-Yves Pierga
9 shared publications- Jean-Yves Pierga
Department of Medical Oncology, Institut Curie - Paris, Université Paris Cité, Paris, France
8 shared publications - Etienne Brain
Department of Medical Oncology, Institut Curie, Saint-Cloud, France
7 shared publications - William Jacot
Department of Medical Oncology, Institut du Cancer Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France
7 shared publications Alain Fourquet
Department of Radiation Oncology Institut Curie Paris France
6 shared publications
Latest Publications
- Open Access
Multiregion profiling of genomic and transcriptional heterogeneity in head and neck squamous-cell carcinoma
- Open Access
CMV seropositivity associates with poor clinical outcome in triple negative breast cancer
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Purpose:In patients with metastatic breast cancer, ≥5 circulating tumor cells (CTC)/7.5 mL of blood is a validated adverse prognostic marker. The STIC CTC phase III trial (N = 778, hormone receptor–positive HER2− metastatic breast cancer) showed that ≥5 CTC/7.5 mL before treatment predicted greater benefit from first-line chemotherapy over endocrine therapy for progression-free (PFS) and overall survival (OS). This exploratory analysis examines these results by histologic subtype, comparing invasive lobular carcinoma (ILC) and carcinoma of no special type (NST).Experimental Design:Baseline CTC count (CellSearch) and its impact on PFS and OS were compared between ILC (N = 159) and NST (N = 571). The survival benefit of chemotherapy in patients with a high CTC count was then re-evaluated separately for each subtype.Results:Before treatment, ILC had significantly higher CTC counts than NST [median, 10 (Q1 = 2, Q3 = 40) vs. 1 (Q1 = 0, Q3 = 7)]. ≥5 CTC/7.5 mL were detected in 64% (95% confidence interval, 56–71) of patients with ILC and 31% (95% confidence interval, 28–35) of patients with NST, correlating with shorter PFS and OS in both. However, patients with ILC and ≥5 CTC/7.5 mL saw no significant benefit from CTC-informed chemotherapy [PFS: HR, 0.91 (0.55–1.52); OS: HR, 0.83 (0.46–1.52)]. In contrast, patients with NST and ≥5 CTC/7.5 mL had markedly improved outcomes with chemotherapy [PFS: HR, 0.54 (0.37–0.81); OS: HR, 0.37 (0.21–0.66)].Conclusions:ILC sheds more CTC than NST, likely owing to underlying biological differences. Although the ≥5 CTC/7.5-mL threshold remained a valid prognostic marker for both, it was predictive of chemotherapy benefit in NST but not in ILC. These findings highlight differences in biomarker utility between ILC and NST, affecting both threshold relevance and treatment response.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Purpose:In patients with metastatic breast cancer, ≥5 circulating tumor cells (CTC)/7.5 mL of blood is a validated adverse prognostic marker. The STIC CTC phase III trial (N = 778, hormone receptor–positive HER2− metastatic breast cancer) showed that ≥5 CTC/7.5 mL before treatment predicted greater benefit from first-line chemotherapy over endocrine therapy for progression-free (PFS) and overall survival (OS). This exploratory analysis examines these results by histologic subtype, comparing invasive lobular carcinoma (ILC) and carcinoma of no special type (NST).Experimental Design:Baseline CTC count (CellSearch) and its impact on PFS and OS were compared between ILC (N = 159) and NST (N = 571). The survival benefit of chemotherapy in patients with a high CTC count was then re-evaluated separately for each subtype.Results:Before treatment, ILC had significantly higher CTC counts than NST [median, 10 (Q1 = 2, Q3 = 40) vs. 1 (Q1 = 0, Q3 = 7)]. ≥5 CTC/7.5 mL were detected in 64% (95% confidence interval, 56–71) of patients with ILC and 31% (95% confidence interval, 28–35) of patients with NST, correlating with shorter PFS and OS in both. However, patients with ILC and ≥5 CTC/7.5 mL saw no significant benefit from CTC-informed chemotherapy [PFS: HR, 0.91 (0.55–1.52); OS: HR, 0.83 (0.46–1.52)]. In contrast, patients with NST and ≥5 CTC/7.5 mL had markedly improved outcomes with chemotherapy [PFS: HR, 0.54 (0.37–0.81); OS: HR, 0.37 (0.21–0.66)].Conclusions:ILC sheds more CTC than NST, likely owing to underlying biological differences. Although the ≥5 CTC/7.5-mL threshold remained a valid prognostic marker for both, it was predictive of chemotherapy benefit in NST but not in ILC. These findings highlight differences in biomarker utility between ILC and NST, affecting both threshold relevance and treatment response.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Patient characteristics according to histological subtype
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Patient characteristics according to histological subtype
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Representativeness of Study Participants
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Representativeness of Study Participants
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Results from univariate and multivariate negative binomial regression models assessing the association between histological subtype and CTC counts
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Results from univariate and multivariate negative binomial regression models assessing the association between histological subtype and CTC counts
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Patient characteristics according to histological subtype and CTC count
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Patient characteristics according to histological subtype and CTC count
- 20 November 2025
- Published by Elsevier in Annals of Oncology
- Vol. 37 (3) , 329-340
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer
- 20 November 2025
- Published by Elsevier in Annals of Oncology
- Vol. 37 (3) , 329-340
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer
- 29 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (24) , 5178-5187
Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Purpose: In patients with metastatic breast cancer, ≥5 circulating tumor cells (CTC)/7.5 mL of blood is a validated adverse prognostic marker. The STIC CTC phase III trial (N = 778, hormone receptor–positive HER2− metastatic breast cancer) showed that ≥5 CTC/7.5 mL before treatment predicted greater benefit from first-line chemotherapy over endocrine therapy for progression-free (PFS) and overall survival (OS). This exploratory analysis examines these results by histologic subtype, comparing invasive lobular carcinoma (ILC) and carcinoma of no special type (NST). Experimental Design: Baseline CTC count (CellSearch) and its impact on PFS and OS were compared between ILC (N = 159) and NST (N = 571). The survival benefit of chemotherapy in patients with a high CTC count was then re-evaluated separately for each subtype. Results: Before treatment, ILC had significantly higher CTC counts than NST [median, 10 (Q1 = 2, Q3 = 40) vs. 1 (Q1 = 0, Q3 = 7)]. ≥5 CTC/7.5 mL were detected in 64% (95% confidence interval, 56–71) of patients with ILC and 31% (95% confidence interval, 28–35) of patients with NST, correlating with shorter PFS and OS in both. However, patients with ILC and ≥5 CTC/7.5 mL saw no significant benefit from CTC-informed chemotherapy [PFS: HR, 0.91 (0.55–1.52); OS: HR, 0.83 (0.46–1.52)]. In contrast, patients with NST and ≥5 CTC/7.5 mL had markedly improved outcomes with chemotherapy [PFS: HR, 0.54 (0.37–0.81); OS: HR, 0.37 (0.21–0.66)]. Conclusions: ILC sheds more CTC than NST, likely owing to underlying biological differences. Although the ≥5 CTC/7.5-mL threshold remained a valid prognostic marker for both, it was predictive of chemotherapy benefit in NST but not in ILC. These findings highlight differences in biomarker utility between ILC and NST, affecting both threshold relevance and treatment response.
- 29 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (24) , 5178-5187
Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial
Purpose: In patients with metastatic breast cancer, ≥5 circulating tumor cells (CTC)/7.5 mL of blood is a validated adverse prognostic marker. The STIC CTC phase III trial (N = 778, hormone receptor–positive HER2− metastatic breast cancer) showed that ≥5 CTC/7.5 mL before treatment predicted greater benefit from first-line chemotherapy over endocrine therapy for progression-free (PFS) and overall survival (OS). This exploratory analysis examines these results by histologic subtype, comparing invasive lobular carcinoma (ILC) and carcinoma of no special type (NST). Experimental Design: Baseline CTC count (CellSearch) and its impact on PFS and OS were compared between ILC (N = 159) and NST (N = 571). The survival benefit of chemotherapy in patients with a high CTC count was then re-evaluated separately for each subtype. Results: Before treatment, ILC had significantly higher CTC counts than NST [median, 10 (Q1 = 2, Q3 = 40) vs. 1 (Q1 = 0, Q3 = 7)]. ≥5 CTC/7.5 mL were detected in 64% (95% confidence interval, 56–71) of patients with ILC and 31% (95% confidence interval, 28–35) of patients with NST, correlating with shorter PFS and OS in both. However, patients with ILC and ≥5 CTC/7.5 mL saw no significant benefit from CTC-informed chemotherapy [PFS: HR, 0.91 (0.55–1.52); OS: HR, 0.83 (0.46–1.52)]. In contrast, patients with NST and ≥5 CTC/7.5 mL had markedly improved outcomes with chemotherapy [PFS: HR, 0.54 (0.37–0.81); OS: HR, 0.37 (0.21–0.66)]. Conclusions: ILC sheds more CTC than NST, likely owing to underlying biological differences. Although the ≥5 CTC/7.5-mL threshold remained a valid prognostic marker for both, it was predictive of chemotherapy benefit in NST but not in ILC. These findings highlight differences in biomarker utility between ILC and NST, affecting both threshold relevance and treatment response.